AstraZeneca (AZN) — Asset Research as of 2026-09-06

Recent Catalysts (roughly June–September 2026)

1. Potential Bristol Myers Squibb (BMY) merger talks (Aug 3, 2026). AstraZeneca shares dropped on Monday, August 3, 2026, after reports emerged that the company had discussed a potential mega-merger with Bristol Myers Squibb [4]. Market commentators, including Rick Ducat, highlighted the report that BMY was in talks to merge with AstraZeneca [6]. This was among the most significant recent catalysts.

2. Sharp single-day decline (July 9, 2026). AZN shares fell roughly 8% as the market opened on July 9, 2026, prompting investors who held the stock to examine losses tied to the drop [3].